Immune Pharma (IMNP) Misses Q4 EPS by 13c

Immune Pharma (NASDAQ: IMNP) reported Q4 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Immune Pharma (IMNP) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Estee Lauder (EL) Tops Q4 EPS by 7c, Beats on Revenue